Home LiteratureArticle Details
PMID: 11945146 Published · ppublish English Journal Article Review

Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection.

Current pharmaceutical design ·Vol. 8 ·No. 11 ·2002-00-00 ·Pages 995-1005

Caradonna L, Mastronardi ML, Magrone T, Cozzolongo R, Cuppone R, Manghisi OG, Caccavo D, Pellegrino NM, Amoroso A, Jirillo E, Amati L

Abstract

Endotoxins or lipopolysaccharides (LPS), major components of the cell wall of Gram-negative bacteria, once released from the bacterial outer membrane bind to specific receptors and, in particular, to a membrane-bound receptor, the CD14 (mCD14) and the toll-like receptor 4 present on monocytes/ macrophages. In turn, LPS-activated monocytes/ macrophages release in the host tissue an array of so-called proinflammatory cytokines and, among them, Tumor Necrosis Factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-8 and IL-12 are the major mediators. Before therapy (To) and at the end of 6-month interferon (IFN)-alpha/Ribavirin (RIB) treatment (T6), circulating endotoxin levels were measured in responder and non responder HCV+ patients. At T0, 57% of the non responders were endotoxin-positive and had, on average, 54 pg/ml of plasma LPS while in 50% of the responder patients endotoxin were found with an average of 29 pg/ml. At T6, in responders LPS were no longer detectable, while in 42% of the non responders LPS were found (average levels 45 pg/ml). In terms of serum cytokine concentration, at T6 IFN-gamma levels when compared to those detected at T0 were increased in both endotoxin-positive and endotoxin-negative patients. However, at T6 IL-10 concentration was significantly increased only in the group of endotoxin-negative subjects (responder patients), in comparison to T0 values. The origin of endotoxemia in HCV+ patients seems to be multifactorial, likely depending on impaired phagocytic functions and reduced T-cell mediated antibacterial activity. In these patients, however, one cannot exclude the passage of LPS from the gut flora to the blood stream, owing a condition of altered intestinal permeability. At the same time, a less efficient detoxification of enteric bacterial antigens at the hepatic level should be taken into consideration. Finally, novel therapeutic attempts aimed to neutralize LPS in the host are discussed.

MeSH Terms
Autoantibodies/blood Cytokines/blood Drug Therapy, Combination Endotoxemia/complications,immunology Hepatitis C/complications,drug therapy,immunology Humans Interferon-alpha/administration & dosage Lactoferrin/immunology Lipopolysaccharides/blood Ribavirin/administration & dosage
Chemicals
Autoantibodies Cytokines Interferon-alpha Lipopolysaccharides Ribavirin Lactoferrin
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Caradonna L
Laboratories of Immunopathology, Scientific Institute for Digestive Diseases, Castellana Grotte, Bari, Italy.
Mastronardi M L
Magrone T
Cozzolongo R
Cuppone R
Manghisi O G
Caccavo D
Pellegrino N M
Amoroso A
Jirillo E
Amati L
Article Info
Journal
Current pharmaceutical design
Abbr.
Curr Pharm Des
ISSN
1381-6128
Published
2002-00-00
Pages
995-1005
Language
English
Region
United Arab Emirates
NLM ID
9602487
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com